Summary

A long-acting basal insulin glargine formulation, 300 U/mL (Gla-300), controlled glycemia as well as insulin glargine 100 U/mL (Gla-100) in patients with type 2 diabetes mellitus (T2DM) but with less nocturnal hypoglycemia. This article presents findings from a Phase 3 multicenter, open-label [EDITION I; NCT01499082] study comparing the two insulin glargine formulations in patients with T2DM who were using basal plus mealtime insulin.